Outlook Therapeutics (OTLK) said Wednesday the US Food and Drug Administration has issued a complete response letter to the ONS-5010 biologics license application resubmission.
The move indicates the regulator cannot approve the application in its present form for the treatment of wet age-related macular degeneration, the company said.
Outlook Therapeutics said it is exploring "all available pathways" for potential clearance in the US and it also plans to continue its efforts to expand into more markets in Europe and other regions.
Trading in shares of Outlook Therapeutics were halted.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments